Den europeiske union - spansk - EMA (European Medicines Agency)

abbott laboratories ltd. - adalimumab - spondylitis, ankylosing; arthritis, rheumatoid; arthritis, psoriatic; crohn disease - inmunosupresores - reumatoide arthritistrudexa en combinación con metotrexato, está indicado para:el tratamiento de moderada a severa, artritis reumatoide activa en pacientes adultos cuando la respuesta a la enfermedad-modificación de las drogas anti-reumáticas, incluyendo metotrexato ha sido insuficiente. el tratamiento de graves, activa y progresiva de la artritis reumatoide en adultos no tratados previamente con metotrexato. trudexa puede ser administrado como monoterapia en caso de intolerancia al metotrexato o cuando el tratamiento continuado con metotrexato es inapropiado. trudexa ha demostrado reducir la tasa de progresión del daño articular medido por rayos x y para mejorar la función física, cuando se administra en combinación con metotrexato. psoriásica arthritistrudexa está indicado para el tratamiento de activo y progresivo de la artritis psoriásica en adultos cuando la respuesta a la anterior modificación de la enfermedad reumática de la terapia de drogas ha sido insuficiente. la espondilitis spondylitistrudexa está indicado para el tratamiento de adultos con espondilitis anquilosante activa grave que han tenido una respuesta inadecuada a la terapia convencional. la enfermedad de crohn diseasetrudexa está indicado para el tratamiento de graves, enfermedad de crohn activa, en pacientes que no han respondido a pesar de un completo y adecuado curso de la terapia con corticosteroides y/o un inmunosupresor; o que son intolerantes o tienen contraindicaciones médicas para este tipo de terapias. para el tratamiento de inducción, trudexa debe administrarse en combinación con cortiocosteroids. trudexa puede ser administrado como monoterapia en caso de intolerancia a los corticosteroides o cuando el tratamiento continuado con corticosteroides es la adecuada (véase la sección 4.

Den europeiske union - tysk - EMA (European Medicines Agency)

abbott laboratories ltd. - adalimumab - spondylitis, ankylosing; arthritis, rheumatoid; arthritis, psoriatic; crohn disease - immunsuppressiva - rheumatoide arthritistrudexa in kombination mit methotrexat ist indiziert zur:behandlung der mittelschweren bis schweren, aktiven rheumatoiden arthritis bei erwachsenen patienten, wenn die response, disease-modifying anti-rheumatic drugs inklusive methotrexat ungeeignet gewesen. die behandlung der schweren, aktiven und progressiven rheumatoiden arthritis bei erwachsenen, die zuvor nicht mit methotrexat behandelt. trudexa als monotherapie im falle einer unverträglichkeit gegenüber methotrexat oder wenn die fortsetzung der behandlung mit methotrexat ungeeignet ist,. trudexa wurde gezeigt, zur verringerung der rate des fortschreitens von gelenkschäden, wie gemessen, durch die x-ray und für die verbesserung der physischen funktion, wenn sie in kombination mit methotrexat. psoriasis-arthritistrudexa ist indiziert zur behandlung der aktiven und progressiven psoriasis-arthritis bei erwachsenen, wenn die reaktion auf die bisherigen disease-modifying anti-rheumatic drug-therapie nicht ausreicht,. morbus spondylitistrudexa ist indiziert für die behandlung von erwachsenen mit schwerer aktiver ankylosierender spondylitis, die haben, die unzureichend auf eine konventionelle therapie. morbus crohn diseasetrudexa ist indiziert zur behandlung des schweren, aktiven morbus crohn bei patienten, die nicht geantwortet haben, trotz einer vollständigen und adäquaten therapie mit einem kortikosteroid und/oder einem immunsuppressivum; oder die intolerant sind oder medizinische kontraindikationen für solche therapien. für die induktion behandlung, trudexa erhalten sollten, in kombination mit cortiocosteroids. trudexa als monotherapie bei unverträglichkeit von kortikosteroiden oder bei fortsetzung der behandlung mit kortikosteroiden ungeeignet ist (siehe abschnitt 4.

Den europeiske union - engelsk - EMA (European Medicines Agency)

abbott laboratories ltd. - adalimumab - spondylitis, ankylosing; arthritis, rheumatoid; arthritis, psoriatic; crohn disease - immunosuppressants - rheumatoid arthritistrudexa in combination with methotrexate, is indicated for:the treatment of moderate to severe, active rheumatoid arthritis in adult patients when the response to disease-modifying anti-rheumatic drugs including methotrexate has been inadequate.the treatment of severe, active and progressive rheumatoid arthritis in adults not previously treated with methotrexate.trudexa can be given as monotherapy in case of intolerance to methotrexate or when continued treatment with methotrexate is inappropriate.trudexa has been shown to reduce the rate of progression of joint damage as measured by x-ray and to improve physical function, when given in combination with methotrexate.psoriatic arthritistrudexa is indicated for the treatment of active and progressive psoriatic arthritis in adults when the response to previous disease-modifying anti-rheumatic drug therapy has been inadequate.ankylosing spondylitistrudexa is indicated for the treatment of adults with severe active ankylosing spondylitis who have had an inadequate response to conventional therapy.crohn's diseasetrudexa is indicated for treatment of severe, active crohn's disease, in patients who have not responded despite a full and adequate course of therapy with a corticosteroid and/or an immunosuppressant; or who are intolerant to or have medical contraindications for such therapies. for induction treatment, trudexa should be given in combination with cortiocosteroids. trudexa can be given as monotherapy in case of intolerance to corticosteroids or when continued treatment with corticosteroids is inappropriate (see section 4.2).

Singapore - engelsk - HSA (Health Sciences Authority)

abbott laboratories (singapore ) private limited - immunology - the abbott prismr hbcore assay is an in vitro chemiluminescent immunoassay (chlia) for the qualitative detection of total antibody to hepatitis b core antigen (anti-hbc) in human serum and plasma. it is intended to be used as a screen for blood and plasma to prevent transmission of hepatitis b virus (hbv) to recipients of blood and blood components and as an aid in the diagnosis of hbv infection. it is also intended for use in testing serum and plasma specimens to screen cell, tissue and organ donors when specimens are obtained while the donor’s heart is still beating. use with abbott prism system.

Singapore - engelsk - HSA (Health Sciences Authority)

abbott laboratories (singapore ) private limited - immunology - the abbott prismr hbsag assay is an in vitro chemiluminescentimmunoassay (chlia) for the qualitative detection of hepatitis b surface antigen (hbsag) in human serum or plasma. it is intended as a screen for donated blood to prevent transmission of hepatitis b virus (hbv) to recipients of blood and blood components and as an aid in the diagnosis of ongoing or previous hepatitis b viral infection. use with abbott prism system. it is also intended for use in testing serum and plasma specimens to screen cell, tissue and organ donors when specimens are obtained while the donor’s heart is still beating.

Singapore - engelsk - HSA (Health Sciences Authority)

abbott laboratories (singapore ) private limited - immunology - the abbott prismr htlv-i/htlv-ii assay is an in vitro chemiluminescent immunoassay (chlia) for the qualitative detection of antibodies to human t-lymphotropic virus type i and/or human t-lymphotropic virus type ii (anti-htlv-i/htlv-ii) in human serum or plasma. the abbott prism htlv-i/htlv-ii (chlia) is intended as a screen for donated blood to prevent transmission of htlv-i and htlv-ii to recipients of blood and blood components and as an aid in the diagnosis of htlv-i and htlv-ii infections. it is also intended for use in testing serum and plasma specimens to screen cell, tissue and organ donors when specimens are obtained while the donor’s heart is still beating. use with abbott prism system.

Singapore - engelsk - HSA (Health Sciences Authority)

abbott laboratories (singapore ) private limited - microbiology - the abbott realtime cmv assay is an in vitro polymerase chain reaction (pcr) assay for the quantification of cytomegalovirus (cmv) dna in human plasma or whole blood. the assay is intended for use in conjunction with clinical presentation and other laboratory markers as an indicator of initiation of therapy and for use as an aid in monitoring viral response to antiviral treatment as measured by changes in plasma or whole blood dna levels. this assay is not intended to be used as a screening for cmv or as a diagnostic test to confirm the presence of cmv infection.

Singapore - engelsk - HSA (Health Sciences Authority)

abbott laboratories (singapore ) private limited - microbiology - the abbott realtime ct/ng assay is an in vitro polymerase chain reaction (pcr) assay for the direct, qualitative detection of the plasmid dna for c. trachomatis and the genomic dna of n. gonorrhoeae in female endocervical or vaginal swab specimens, male urethral swab specimens, or in male and female urine specimens.

Singapore - engelsk - HSA (Health Sciences Authority)

abbott laboratories (singapore ) private limited - microbiology - it is an in vitro polymerase chain reaction (pcr) assay for the quantitation of hepatitis b virus (hbv) dna in human plasma or serum from hbv‑infected individuals. the abbott realtime hbv assay is intended for use in conjunction with clinical presentation and other laboratory markers as an indicator of disease prognosis and for use as an aid in assessing viral response to antiviral treatment as measured by changes in plasma or serum hbv dna levels. this assay is not intended for use as a screening test for hbv or as a diagnostic test to confirm the presence of hbv infection.

Singapore - engelsk - HSA (Health Sciences Authority)

abbott laboratories (singapore ) private limited - microbiology - it is an in vitro reverse transcription-polymerase chain reaction (rt‑pcr) assay for the quantitation of hepatitis c viral ribonucleic acid (hcv rna) in human serum and plasma from hcv-infected individuals. the abbott realtime hcv assay is intendedfor use as an aid in the management of hcv-infected patients undergoing antiviral therapy. the abbott realtime hcv assay is not for screening blood, plasma, serum or tissue donors for hcv,or to be used as a diagnostic test to confirm the presence of hcv infection.